JP2023514056A5 - - Google Patents
Info
- Publication number
- JP2023514056A5 JP2023514056A5 JP2022544294A JP2022544294A JP2023514056A5 JP 2023514056 A5 JP2023514056 A5 JP 2023514056A5 JP 2022544294 A JP2022544294 A JP 2022544294A JP 2022544294 A JP2022544294 A JP 2022544294A JP 2023514056 A5 JP2023514056 A5 JP 2023514056A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971548P | 2020-02-07 | 2020-02-07 | |
| US62/971,548 | 2020-02-07 | ||
| US202063029066P | 2020-05-22 | 2020-05-22 | |
| US63/029,066 | 2020-05-22 | ||
| US202063069405P | 2020-08-24 | 2020-08-24 | |
| US63/069,405 | 2020-08-24 | ||
| US202063088038P | 2020-10-06 | 2020-10-06 | |
| US63/088,038 | 2020-10-06 | ||
| US202063092039P | 2020-10-15 | 2020-10-15 | |
| US63/092,039 | 2020-10-15 | ||
| US202063105679P | 2020-10-26 | 2020-10-26 | |
| US63/105,679 | 2020-10-26 | ||
| US202063107053P | 2020-10-29 | 2020-10-29 | |
| US63/107,053 | 2020-10-29 | ||
| US202163139594P | 2021-01-20 | 2021-01-20 | |
| US63/139,594 | 2021-01-20 | ||
| PCT/US2021/016764 WO2021158884A1 (en) | 2020-02-07 | 2021-02-05 | Treatment regimen for cancer using immunomodulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514056A JP2023514056A (ja) | 2023-04-05 |
| JP2023514056A5 true JP2023514056A5 (https=) | 2023-12-04 |
Family
ID=77200870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544294A Pending JP2023514056A (ja) | 2020-02-07 | 2021-02-05 | 免疫調節を使用した癌の治療レジメン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230338402A1 (https=) |
| EP (1) | EP4099994A4 (https=) |
| JP (1) | JP2023514056A (https=) |
| WO (1) | WO2021158884A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250179502A1 (en) * | 2022-02-28 | 2025-06-05 | University Of Massachusetts | Targeting neuropilin 2 (nrp2) in lethal prostate cancer |
| WO2024073010A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Cincinnati | Inhibition of natural killer cell cytoxocity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991628C (en) * | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| MY192158A (en) * | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| CA3121270A1 (en) * | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Novel approach for treatment of cancer using immunomodulation |
-
2021
- 2021-02-05 WO PCT/US2021/016764 patent/WO2021158884A1/en not_active Ceased
- 2021-02-05 EP EP21750508.0A patent/EP4099994A4/en not_active Withdrawn
- 2021-02-05 JP JP2022544294A patent/JP2023514056A/ja active Pending
- 2021-02-05 US US17/797,388 patent/US20230338402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514056A5 (https=) | ||
| AU2020231236A1 (en) | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2023542608A5 (https=) | ||
| CN108159038A (zh) | 一种药物组合物及其在制备治疗肿瘤多药耐药性的药物中的用途 | |
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2023102786A5 (https=) | ||
| Fukuoka et al. | Clinical studies of irinotecan alone and in combination with cisplatin | |
| Sun et al. | Phase II study of S-1 plus cisplatin as first-line therapy in patients with metastatic esophageal carcinoma | |
| US20190275021A1 (en) | Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer | |
| US9375411B2 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| Sato et al. | A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen | |
| JP2023514056A (ja) | 免疫調節を使用した癌の治療レジメン | |
| Macdonald et al. | A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339) | |
| CN112423753A (zh) | 降低急性髓样白血病的复发风险和延长生存的方法和组合物 | |
| JP2024520307A5 (https=) | ||
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака | |
| Sharma et al. | Kisquali (Ribociclib): A promising therapeutic candidate against breast cancer | |
| KR20240046527A (ko) | 암치료를 위한 신규 경구용 약학적 조성물 | |
| WO2025166944A1 (en) | Methods of treatment using an ezh2 modulator | |
| Nieken et al. | Outpatient-based subcutaneous interleukin-2 monotherapy in advanced renal cell carcinoma: an update | |
| Kuchar et al. | Axitinib in sequential therapy in metastatic renal cell carcinoma | |
| Tang et al. | Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis | |
| Killock | An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC |